Revolution Medicines’ pancreatic cancer drug Rasonque delivered a high-velocity commercial start after U.S. approval, with the company reporting $198 million in sales in just five weeks. Revolution said more than 5,000 patients have been treated since launch, and the early performance is prompting analysts to reset forecasts for the pan-RAS inhibitor. The sales surge follows investor attention on whether the initial approval translates into durable uptake across the commercial footprint. The reported debut also reinforces the market’s appetite for molecularly targeted oncology drugs with clear biomarker definitions.